The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of sorafenib (S) and dacarbazine (D) in leiomyosarcoma (LMS), synovial sarcoma (SS), and malignant peripheral nerve sheath tumor (MPNST).
D. R. D'Adamo
Honoraria - Bayer
Research Funding - Bayer
M. L. Keohan
No relevant relationships to disclose
R. D. Carvajal
No relevant relationships to disclose
M. L. Hensley
No relevant relationships to disclose
C. Hirst
No relevant relationships to disclose
L. Qin
No relevant relationships to disclose
C. Antonescu
No relevant relationships to disclose
R. A. Lefkowitz
No relevant relationships to disclose
G. K. Schwartz
No relevant relationships to disclose
R. G. Maki
Honoraria - Bayer